Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

INTRODUCTION: Albiglutide, a selective once-weekly glucagon-like peptide-1 receptor agonist, is being developed for the treatment of type 2 diabetes mellitus. Albiglutide’s effect on cardiac repolarization (QTc interval) was assessed in a randomized, double-blind, placebo-controlled, parallel-group...

Descripción completa

Detalles Bibliográficos
Autores principales: Darpo, Borje, Zhou, Meijian, Matthews, Jessica, Zhi, Hui, Young, Malcolm A., Perry, Caroline, Reinhardt, Rickey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065291/
https://www.ncbi.nlm.nih.gov/pubmed/24510375
http://dx.doi.org/10.1007/s13300-014-0055-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065291/
https://www.ncbi.nlm.nih.gov/pubmed/24510375
http://dx.doi.org/10.1007/s13300-014-0055-1

Ejemplares similares